NK cells with inducible expression of CAR as novel immunotherapy increasing the efficacy of monoclonal antibodies.

2016/23/B/NZ5/02622

Keywords

Descriptors

  • NZ5_7: Leczenie chorób człowieka

Panel

NZ5 – Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)

Host institution

Warszawski Uniwersytet Medyczny, Wydział Lekarski

Voivodeship: mazowieckie

Other projects carried out by the institution »

Principal investigator (from the host institution)

dr Beata Pyrzyńska

Number of co-investigators in the project: 4

Call

OPUS 12 – announced on 2016-09-15

Amount awarded
1 651 770 PLN
Project start date
2017-08-01
Project end date
2022-07-31
Project duration
60 months (the same as in the proposal)
Project status
Project settled

Project description

Download the project description in a pdf file

Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.

Information in the final report

Publication in academic press/journals (2)

  1. NK Cell Degranulation Triggered by Rituximab Identifies Potential Markers of Subpopulations with Enhanced Cytotoxicity toward Malignant B Cells.

    Authors:
    Wlodarczyk M., Torun A., Zerrouqi A., Pyrzynska B.
    Academic press:
    International Journal of Molecular Sciences (year: 2024, volume: 25, pages: 8980), Publisher: MDPI
    Status:
    Published
    DOI:
    10.3390/ijms25168980 – link to the publication
  2. CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy Against Cancer.

    Authors:
    Włodarczyk M, Pyrzyńska B.
    Academic press:
    Cancers (year: 2023, volume: 15(1), pages: 117-132), Publisher: MDPI
    Status:
    Published
    DOI:
    10.3390/cancers15010117 – link to the publication

Articles in post-conference publications (2)

  1. Salinomycin expands the cytotoxicity of both anti-CD20 monoclonal antibodies and natural killer cells towards non-Hodgkin lymphomas.

    Authors:
    Zerrouqi A., Miazek-Zapala N., Torun A., Zapala P., Golab J., Winiarska M., Pyrzynska B.
    Conference:
    Annual Meeting of the American Association for Cancer Research (AACR), Atlanta, GA, USA (year: 2019, pages: Cancer Research 79(13S):LB-261), Publisher: AACR
    Date:
    conference 43553
    Status:
    Published
  2. Natural killer immune response is promoted by the treatment of B-cell lymphoma cancer cells with membrane ionophores.

    Authors:
    Zerrouqi A., Torun A., Miazek N., Pilch Z., Golab J., Pyrzynska B.
    Conference:
    AACR Special Conference on Tumor Immunology and Immunotherapy, Boston, MA, USA (year: 2020, pages: CANCER IMMUNOLOGY RESEARCH 8(3S):92-93; Abs. B14), Publisher: AACR
    Date:
    conference 43786
    Status:
    Published

« New search

Graphic design and implementation: Jakub Piotrowski